Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn&apos;s disease: post hoc results from the phase 3b SEQUENCE trial

Inflammatory Bowel Disease

Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE Study

Am J Gastroenterol

Loftus EV Jr, Joshi N, Sands BE, Jairath V, Blumenstein I, Shukla N, Kligys K, Anschutz T, Griffith J, Zambrano J, Louis E

doi: 10.14309/ajg.0000000000004044

Inflammatory Bowel Disease

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

J Crohns Colitis

Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK

doi: 10.1093/ecco-jcc/jjaf213

Inflammatory Bowel Disease

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

J Crohns Colitis

De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group

doi: 10.1093/ecco-jcc/jjag011

Inflammatory Bowel Disease

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial

Inflamm Bowel Dis

Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators

doi: 10.1093/ibd/izag055

Further Publications

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

Minerva Gastroenterol (Torino)

Moon S, Choi YJ, Shin S

doi: 10.23736/S2724-5985.26.04084-2

Inflammatory Bowel Disease

An Enhanced Treatment Algorithm Targeting Mucosal Healing is Effective and Safe in Older Patients with Crohn's Disease: A Post-hoc Analysis of the REACT2 Trial

Am J Gastroenterol

Goodwin SW, Vuyyuru SK, Sedano R, Zou G, Dulai PS, Singh S, Narula N, Ma C, Jairath V

doi: 10.14309/ajg.0000000000004015

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

J Gastroenterol Hepatol

Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X

doi: 10.1111/jgh.70634

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Jairath V, Kierkuś J, Duvall GA, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Reinisch W

doi: 10.1016/S2468-1253(26)00119-6

Inflammatory Bowel Disease

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis

Adv Ther

Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB

doi: 10.1007/s12325-025-03447-6

Gastroenterology

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial

Related content

Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE Study

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

An Enhanced Treatment Algorithm Targeting Mucosal Healing is Effective and Safe in Older Patients with Crohn's Disease: A Post-hoc Analysis of the REACT2 Trial

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis